1. Home
  2. EVO vs CHI Comparison

EVO vs CHI Comparison

Compare EVO & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.72

Market Cap

994.5M

Sector

Health Care

ML Signal

HOLD

Logo Calamos Convertible Opportunities and Income Fund

CHI

Calamos Convertible Opportunities and Income Fund

HOLD

Current Price

$12.70

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
CHI
Founded
1993
2002
Country
Germany
United States
Employees
4553
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
994.5M
1.0B
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
EVO
CHI
Price
$2.72
$12.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
28.7K
153.5K
Earning Date
04-08-2026
01-01-0001
Dividend Yield
N/A
9.90%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.37
N/A
Revenue Next Year
$10.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$10.00
52 Week High
$4.42
$12.90

Technical Indicators

Market Signals
Indicator
EVO
CHI
Relative Strength Index (RSI) 42.69 54.08
Support Level $2.63 $10.91
Resistance Level $3.82 $12.80
Average True Range (ATR) 0.07 0.22
MACD -0.03 -0.03
Stochastic Oscillator 27.55 40.41

Price Performance

Historical Comparison
EVO
CHI

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

About CHI Calamos Convertible Opportunities and Income Fund

CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.

Share on Social Networks: